How to Start a Ketamine Therapy Practice: A Clinician's Guide

Starting a ketamine therapy practice begins with authority, safety systems, and a care model your team can actually support. This how to start a ketamine therapy practice a clinician s guide explains the operational questions clinicians should resolve before offering treatment, including controlled-substance requirements, patient selection, monitoring, documentation, medication sourcing, and follow-up care.

Ketamine is a Schedule III controlled substance under the federal Controlled Substances Act. It is used off label in some clinical settings for psychiatric and pain-related indications. Esketamine nasal spray is an FDA-approved product with its own Risk Evaluation and Mitigation Strategy, or REMS, requirements.

1. Confirm federal and state authority before selecting a care model

Federal registration is the first operational check. The DEA Practitioner’s Manual explains registration, recordkeeping, security, ordering, and disposal expectations for controlled substances. Review your registration schedule, registered business address, and whether a new practice location requires a separate registration or other action before obtaining or administering ketamine.

State rules can affect who may prescribe or administer ketamine, required physician supervision, facility standards, telemedicine workflows, and prescription drug monitoring program reporting. Confirm requirements with the state medical board, state pharmacy board, and counsel familiar with controlled-substance practice in your state. An off-label indication does not remove ordinary controlled-substance, medical-record, or professional-practice obligations.

Telehealth needs separate review. A remote intake, remote follow-up, and remote prescription may be governed differently. Build a workflow that verifies the patient’s location, the clinician’s authority in that location, identity checks, clinical escalation pathways, and applicable federal or state prescribing conditions. See our guide to telehealth ketamine protocols for clinical workflow context.

2. Choose a practice model that matches your clinical capacity

Route of administration determines much of the operational burden. IV infusion care generally requires a higher level of on-site monitoring and emergency readiness than an in-office oral or sublingual model. Define what the practice can safely support before promoting a service line.

For each route, specify the setting, staff roles, required observations, emergency equipment, medication storage, transport-home policy, and escalation plan. Do not copy a protocol from another setting without reviewing whether its staffing and equipment assumptions match yours.

A useful facility review includes blood-pressure measurement, pulse oximetry where clinically appropriate, oxygen and suction availability, emergency medications and supplies, infection-control procedures, and staff training. Facility licensing and emergency-capability requirements vary by jurisdiction.

Cardiovascular screening and monitoring deserve particular attention because ketamine can increase blood pressure and heart rate. Our overview of cardiovascular monitoring explains why baseline assessment, defined thresholds, and documented reassessment matter.

3. Build patient selection and informed-consent protocols

Written selection criteria make referrals more consistent and reduce avoidable variation between clinicians. A comprehensive intake should address the target diagnosis, symptom severity, prior treatments, current medications, substance-use history, psychosis screening, cardiovascular history, pregnancy status where relevant, and the patient’s ability to follow post-treatment safety instructions.

Use validated measures to establish a baseline and follow response over time. PHQ-9 and MADRS are examples of depression measures used in clinical care and research. A score alone should not determine treatment eligibility. Interpret it alongside diagnostic assessment, safety assessment, functional change, adverse effects, and the patient’s broader treatment plan.

According to the 2017 JAMA Psychiatry consensus statement on ketamine for mood disorders, ketamine use for mood disorders requires careful patient selection, informed consent, monitoring, and attention to abuse potential. Use the full statement as clinical context when developing local protocols.

Consent should plainly explain the intended use, expected short-term effects, known risks, alternatives, uncertainty around long-term maintenance approaches, financial responsibility, and what happens if symptoms worsen or an adverse event occurs. For psychiatric uses of racemic ketamine, explain that this differs from FDA-approved esketamine nasal spray.

4. Turn clinical protocols into repeatable session workflows

A protocol is useful only when staff can follow it consistently. Create separate written procedures for intake, pre-treatment review, administration, monitoring, adverse-event response, discharge, and follow-up. Define which clinician can change a dose, pause a session, or refer a patient for a higher level of care.

Include the route, dose range, titration principles, monitoring intervals, observation period, discharge criteria, and criteria for discontinuation. Avoid presenting one dose as universally appropriate. Route, indication, comorbidities, concurrent medications, response, and adverse effects can all affect clinical decisions.

Medication interactions should be reviewed before each treatment series and when a patient’s regimen changes. See our guides to ketamine drug interactions and ketamine and benzodiazepines for patient-facing context that can support, but not replace, clinician judgment.

5. Vet medication sourcing and compounding arrangements

Practices using compounded ketamine should understand the difference between patient-specific compounding and outsourcing. Section 503A pharmacies generally compound drugs pursuant to individual patient prescriptions. Section 503B outsourcing facilities may compound eligible drugs in larger quantities under a different federal framework.

The FDA states that compounded drugs are not FDA approved, and quality oversight differs from approval of a commercially manufactured drug. Review the pharmacy’s licensure, applicable compounding category, formulation records, testing documentation where relevant, shipping process, complaint handling, and communication process for dose or formulation changes.

FDA guidance on human drug compounding is a primary source for this review. Keep due-diligence records current, especially when changing pharmacies or formulations.

6. Plan documentation, staffing, and financial operations together

Documentation should show the clinical rationale for care and what occurred at each encounter. Record the indication, relevant history, consent discussion, screening findings, baseline and follow-up measures, dose and route, monitoring, adverse effects, discharge assessment, and follow-up plan.

Staff training should cover the practice’s actual protocols, not just general ketamine education. Train everyone who monitors patients to recognize expected effects, identify concerning changes, initiate emergency procedures, document observations, and know when to contact the prescribing clinician. Regular drills can reveal gaps in role assignment or equipment access before a real event.

Financial planning should separate clinical services, medication acquisition or dispensing arrangements, staff observation time, equipment, administrative work, and insurer requirements. Off-label racemic ketamine may be self-pay or have limited coverage depending on the payer and service. Do not promise reimbursement. Verify coding and coverage policies with the payer or a qualified billing adviser before making patient-facing statements.

7. Build referral and continuity-of-care pathways

Ketamine care should fit within a wider treatment plan. Establish clear intake criteria for psychiatrists, primary-care clinicians, pain specialists, and therapists who refer patients. With patient authorization, define what information is shared back, who manages concurrent medications, and what happens when a patient needs urgent psychiatric assessment or a different level of care.

Referral partners need practical information: who may be appropriate, what evaluation is required, how long intake takes, what monitoring occurs, and how treatment response will be communicated. Clinicians assessing treatment-resistant depression can review next steps for treatment-resistant depression for broader care context.

Starting small can be sensible. A limited launch with audited charts, scheduled protocol review, and clear capacity limits gives the team a chance to correct documentation or workflow gaps before expanding.